Iovance Biotherapeutics (US.IOVA)
Capital Allocation Audit · Period: 2010 – 2026
Key Metrics
US.IOVA · YoY: 2026 Q1 vs 2025 Q1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 109.2% | → |
| ROE | -11.0% | ↑ |
| Cash Conversion | - | → |
| D/E Ratio | 0.07 | ↑ |
| Gross Margin | 40.5% | ↑ |
US.IOVA (Iovance Biotherapeutics) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY ---------------------------- FCF Conversion 109.2% → ROE -11.0% ↑ Cash Conversion - → D/E Ratio 0.07 ↑ Gross Margin 40.5% ↑
Key Metrics
US.IOVA (Iovance Biotherapeutics) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY----------------------------FCF Conversion 109.2% →ROE -11.0% ↑Cash Conversion - →D/E Ratio 0.07 ↑Gross Margin 40.5% ↑Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies